Previous 10 | Next 10 |
Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosis Exchange of $6.9 million principal amount of outstanding promissory notes into private placement strengthens balance sheet NEW YORK, Ju...
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has enter...
Received ~$2.52 million in aggregate CIR payments in 2020 CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company spe...
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-system...
AzurRx BioPharma ( AZRX +7.3% ) announces that it will conduct its Phase 2 clinical trial, OPTION 2, evaluating lead candidate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency in Therapeutics Development Network (TDN) sites. More news on: AzurRx BioPharma,...
On track to initiate the OPTION 2 trial by the end of Q2 2020 OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsules Trial completion and top-line data expected in Q1 2021 NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- AzurR...
NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following le...
NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX) Click here to view Full Argus Report. Highlights, as conveyed by Argus Analy...
NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it h...
BROOKLYN, NY / ACCESSWIRE / April 15, 2020 / AzurRx BioPharma, Inc. (NASDAQ:AZRX), is a clinical stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases, today announced that it will be presenting at the Planet MicroCa...
News, Short Squeeze, Breakout and More Instantly...
AzurRx BioPharma Inc. Company Name:
AZRX Stock Symbol:
NASDAQ Market:
AzurRx BioPharma Inc. Website:
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (G...
Why Investors Are Watching These 3 Penny Stocks Right Now There are plenty of ways to find the best penny stocks to buy right now. And, one method that many penny stocks investors use is looking at what top investors are buying alongside other metrics. While this can be a good strat...
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...